0000899243-20-003027.txt : 20200204
0000899243-20-003027.hdr.sgml : 20200204
20200204204530
ACCESSION NUMBER: 0000899243-20-003027
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200201
FILED AS OF DATE: 20200204
DATE AS OF CHANGE: 20200204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON DAVID LEE
CENTRAL INDEX KEY: 0001733883
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 20576040
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS
STREET 2: 171 OYSTER POINT BLVD, STE. 300
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 171 OYSTER POINT BLVD, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-01
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001733883
JOHNSON DAVID LEE
C/O GLOBAL BLOOD THERAPEUTICS, INC.
171 OYSTER POINT BLVD., SUITE 300
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Commercial Officer
Common Stock
2020-01-31
5
A
0
E
310
36.68
A
11227
D
Common Stock
2020-02-01
4
M
0
3125
A
14352
D
Common Stock
2020-02-01
4
F
0
1167
65.26
D
13185
D
Restricted Stock Units
2020-02-01
4
M
0
3125
0.00
D
Common Stock
3125
18750
D
Restricted Stock Units
2020-02-03
4
A
0
29160
0.00
A
Common Stock
29160
29160
D
Stock Option (Right to Buy)
65.82
2020-02-03
4
A
0
38500
0.00
A
2030-02-02
Common Stock
38500
38500
D
Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,125 shares of Common Stock underlying the Reporting Person's RSUs.
The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2020, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
/s/ Lesley Ann Calhoun, Attorney-in-Fact
2020-02-04